Study Title

pointbiopharma

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Study Details

Description:

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States































© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468